On October 14, 2025, BioXcel Therapeutics, Inc. announced positive findings from a study correlating efficacy measures for its drug BXCL501, showing strong correlations (ρ=0.89; p<0.0001) between clinician and patient assessments. This data will be included in a supplemental New Drug Application planned for submission in Q1 2026.